Ken Griffin Tango Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$7.36 - $11.93 $3,680 - $5,965
500 Added 50.0%
1,500 $11,000
Q2 2024

Aug 14, 2024
SELL
$6.66 - $10.15 $3,996 - $6,090
-600 Reduced 37.5%
1,000 $8,000
Q1 2024

May 15, 2024
BUY
$7.51 - $12.88 $12,016 - $20,608
1,600 New
1,600 $12,000

Others Institutions Holding TNGX

# of Institutions
123
Shares Held
91.7M
Call Options Held
3.1K
Put Options Held
1.5K
View Full List

About Tango Therapeutics, Inc.

TNGX Quotes by TradingView
  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $273M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email